CCCC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
8.5M
+27.5%
6.6M
+7.9%
6.2M
-44.2%
11.0M
-1.9%
11.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
8.5M
+27.5%
6.6M
+7.9%
6.2M
-44.2%
11.0M
-1.9%
11.2M
Operating Expenses
33.1M
+0.0%
33.1M
-2.6%
33.9M
-0.7%
34.2M
-25.2%
45.6M
R&D
24.8M
+1.4%
24.5M
-0.5%
24.6M
-1.5%
25.0M
-3.9%
26.0M
SG&A
8.3M
-3.9%
8.6M
-7.9%
9.3M
+1.7%
9.2M
+2.9%
8.9M
Operating Income
-24596000
+6.9%
-26423000
+4.9%
-27785000
-20.0%
-23145000
+32.7%
-34412000
EBITDA
-24276000
+7.1%
-26131000
+4.6%
-27381000
-20.5%
-22717000
+2.2%
-23219000
Net Income
-21843000
+7.6%
-23635000
+5.9%
-25129000
-22.7%
-20486000
+36.3%
-32166000
EPS (Basic)
$-0.16
+11.1%
$-0.18
+10.0%
$-0.20
-17.6%
$-0.17
+61.4%
$-0.44
EPS (Diluted)
$-0.16
+11.1%
$-0.18
+10.0%
$-0.20
-17.6%
$-0.17
+61.4%
$-0.44
Shares (Diluted)
136.1M
+4.1%
130.7M
+3.7%
126.1M
+7.6%
117.2M
+61.5%
72.6M
C4 Therapeutics (CCCC) — Financials